Monthly Reports

Each month we publish a snapshot of how the US clinical trial recruiting pipeline is changing — which drugs are gaining ground, which are slipping, which are entering for the first time, and which have exited recruiting entirely. Built from monthly captures of the public ClinicalTrials.gov registry.

• Issue 4 · August 2026

  The US Clinical Trial Recruiting Pipeline: July → August 2026

  Pumitamig expands to 21 recruiting trials across 32 conditions while still sitting on two sponsors, and two of last issue's three calls break. 206 drugs exited recruiting, 219 entered.

• Issue 3 · July 2026

  The US Clinical Trial Recruiting Pipeline: June → July 2026

  One month of movement, and a continuity check on the drugs we've been tracking. 480 drugs exited recruiting, 559 entered.

• Issue 2 · June 2026

  The US Clinical Trial Recruiting Pipeline: May → June 2026

  A quiet month — and a continuity check on last issue's two calls. Tirzepatide's surge cooled to flat, Keytruda's slide held. 181 drugs exited recruiting, 343 entered.

• Issue 1 · May 2026

  The US Clinical Trial Recruiting Pipeline: March → May 2026

  Two months of change. Tirzepatide accelerates, Keytruda decelerates, 617 drugs exited recruiting, 453 entered.